Some forms of blood cancer, such as multiple myeloma and lymphoma, are malignant diseases that originate from immune cells, specifically lymphocytes. In recent years, CAR-T cell therapies have become ...

Lyell Immunopharma, Inc. has announced plans to accelerate the development of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell therapy for aggressive large B-cell lymphoma, with pivotal trials expected ...

Cancer isn't just about broken genes-it's about broken architecture. Imagine a city where roads suddenly vanish, cutting off neighborhoods from essential services. That's what happens inside cells ...

Translocations are chromosomal “cut and paste” errors that drive many lymphomas, a type of blood cancer and the sixth most common form of cancer overall. This includes mantle cell lymphoma, a rare but ...

For the first time, Weill Cornell Medicine researchers have demonstrated that Hodgkin lymphoma cancer cells from patient samples are immune cells stuck in an "identity crisis." Normally, a B cell ...

Lymphomas belong to the group of malignant diseases of the immune system and mainly affect the organs of the lymphatic system. Anaplastic large cell lymphoma (ALCL) belongs to the subgroup of ...

In the largest study of its kind, researchers from The University of Texas MD Anderson Cancer Center identified three subgroups of patients with large B-cell lymphoma (LBCL) who have different levels ...

Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During their preparation for this battle, B cells transiently revert to a more ...

In addition to a high rate of deaths, ADC Therapeutics’ Zynlonta plus rituximab showed no overall survival benefit in ...

Lupeng Pharmaceutical today announced that the National Medical Products Administration (NMPA) has granted accelerated approval to rocbrutinib (development code: LP-168) for the treatment of adult ...